Novartis Unwinds Roche Ties With $20.7 Billion Stake Sale.

For Novartis, the deal was attractive because Roche was willing to buy back the whole stake in a single transaction, allowing a clean exit, spokesman Jarvis said. Novartis owns 33% of Roche's voting shares, and Novartis has made a 10% annual gain on them over the past two decades. [Extracted from the article]